FDA Panel Says Breast Transilluminators Should Remain Class III
This article was originally published in The Gray Sheet
Executive Summary
FDA’s Radiological Devices Panel recommends that pre-amendment breast transilluminator devices should stay as class III devices.
You may also be interested in...
New PMA Requirement Proposed For Apparently Nonexistent Devices
CDRH is proposing to require PMAs for four categories of devices for the first time, but it is not likely to hear much resistance from industry
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.